Ascidian and Lilly Sign $1.9B Kidney Disease RNA Deal
BOSTON, Massachusetts, USA, June 3, 2026 Ascidian Therapeutics and Eli Lilly and Company have entered into a landmark global...
Eli Lilly
Advertisement
Lilly’s Retevmo Cuts Recurrence Risk by 83% in NSCLC
INDIANAPOLIS, Indiana, May 31, 2026 Eli Lilly and Company has announced groundbreaking results from the pivotal Phase 3 LIBRETTO-432...
Hanmi and Lilly Strike $1.26 Billion Deal for Promising GLP-2 Drug Candidate Sonefpeglutide
SEOUL, South Korea, June 1, 2026 Hanmi Pharm. Co., Ltd. has entered into a landmark global licensing agreement with...
Lilly Unveils Landmark Phase 3 Data for Foundayo and Retatrutide at ADA 2026
INDIANAPOLIS, May 28, 2026 Eli Lilly and Company has announced a major slate of scientific presentations for the American...
Merz and Kvvit Partner to Expand INBRIJA Access
FRANKFURT, Germany and GANZHOU, China, May 26, 2026 Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. have announced...
Advertisements
Lilly Acquires Curevo, LimmaTech and Vaccine Company
INDIANAPOLIS, United States, May 26, 2026 Eli Lilly and Company has announced three major biotechnology acquisitions aimed at significantly...
Lilly’s VERVE-102 Shows Durable LDL-C Reduction
Indianapolis, Indiana, USA, May 25, 2026 Eli Lilly and Company has announced positive Phase 1b clinical results for VERVE-102,...
Lilly’s Foundayo Shows Strong Weight Loss in Seniors
Indianapolis, Indiana, USA – May 22, 2026 Eli Lilly and Company announced new clinical analysis from the Phase 3...
Lilly Acquires Engage Bio for Genetic Medicines
SAN CARLOS, Calif., May 22, 2026 Eli Lilly and Company has acquired Engage Bio, a preclinical biotechnology company focused...
Eli Lilly Retatrutide Phase 3 Trial Delivers Major Weight Loss
INDIANAPOLIS, May 21, 2026 Eli Lilly and Company announced positive topline results from its pivotal Phase 3 TRIUMPH-1 clinical...
Advertisement
